Martin Adelson, Ph.D.
Dr. Adelson (Chief Operating Officer, Genesis Biotechnology Group) is one of the members in the Scientific Advisory Board and has been providing advice to the assay development. He has extensive expertise in the development and commercialization of quality diagnostic tests through CAP-accredited CLIA laboratory in Medical Diagnostic Laboratories in Hamilton, New Jersey. His team has developed a large number of PCR-based diagnostic assays for the detection and management of infectious diseases and cancer screening and offers these services to thousands of physicians across the United States, as well as internationally. He will provide assistance in product development including generating industry standard operating procedures, as well as assisting in future FDA submissions. He has sat on the Editorial Board for the Journal of Clinical Microbiology and for Diagnostic Microbiology and Infectious Disease, and is currently a member of the American Society for Microbiology, the International Organization for Mycoplasmology, the Thomas Jefferson University Biotechnology Program Advisory Committee, and the Association for Molecular Pathology. Dr. Adelson holds a certificate of qualification from the New York State Department of Health and has published close to fifty articles in the field of biotechnology.